Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 20.95% is in line with its 5-year average of 20.20%, around the middle of its 5-year range (13.85%–24.04%).
4.84% below its 12-month average of 22.01%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 23.40%.
EBITDA MARGIN
20.95%
EBITDA MARGIN AVG TTM
22.01%
EBITDA MARGIN AVG 3Y
21.90%
EBITDA MARGIN AVG 5Y
20.20%
EBITDA MARGIN AVG 10Y
18.46%
EBITDA MARGIN AVG 15Y
17.91%
EBITDA MARGIN AVG 20Y
17.45%
CURRENT VS TTM AVG
-4.84%
CURRENT VS 3Y AVG
-4.33%
CURRENT VS 5Y AVG
+3.73%
CURRENT VS 10Y AVG
+13.48%
CURRENT VS 15Y AVG
+16.95%
CURRENT VS 20Y AVG
+20.03%
HealthStream, Inc.
Market Cap
$914.14M
EBITDA Margin
20.95%
TTM Avg
22.01%
3Y Avg
21.90%
5Y Avg
20.20%
Market Cap
$900.79M
EBITDA Margin
-189.51%
TTM Avg
-701.94%
3Y Avg
-497.69%
5Y Avg
-575.23%
Market Cap
$931.96M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$888.80M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$944.30M
EBITDA Margin
-5250.17%
TTM Avg
-5250.17%
3Y Avg
-5250.17%
5Y Avg
-5250.17%
Market Cap
$948.82M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$877.41M
EBITDA Margin
43.46%
TTM Avg
29.10%
3Y Avg
-0.91%
5Y Avg
-6.21%
Market Cap
$957.88M
EBITDA Margin
-448.41%
TTM Avg
-402.69%
3Y Avg
-402.69%
5Y Avg
-402.69%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HealthStream, Inc. (HSTM) | $914.14M | 20.95% | 22.01% | 21.90% | 20.20% |
| Arbutus Biopharma Corp (ABUS)vs › | $900.79M | -189.51% | -701.94% | -497.69% | -575.23% |
| CeriBell, Inc. (CBLL)vs › | $931.96M | -64.07% | -61.50% | -81.15% | -81.15% |
| Bioventus Inc. (BVS)vs › | $895.91M | 18.58% | 12.56% | -0.37% | 4.16% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $888.80M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $944.30M | -5250.17% | -5250.17% | -5250.17% | -5250.17% |
| MoonLake Immunotherapeutics (MLTX)vs › | $948.82M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $877.41M | 43.46% | 29.10% | -0.91% | -6.21% |
| Kura Oncology, Inc. (KURA)vs › | $957.88M | -448.41% | -402.69% | -402.69% | -402.69% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $858.31M | -37.08% | -66.80% | -66.80% | -66.80% |
Gross Margin
65.1%
EBITDA Margin
20.9%
Operating Margin
8.0%
Net Margin
6.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 23.40% |
| 2026-03-31 | 23.25% |
| 2025-12-31 | 16.86% |
| 2025-09-30 | 24.04% |
| 2025-06-30 | 22.52% |
| 2025-03-31 | 20.59% |
| 2024-12-31 | 20.41% |
| 2024-09-30 | 22.67% |
| 2024-06-30 | 20.66% |
| 2024-03-31 | 22.03% |
| 2023-12-31 | 20.94% |
| 2023-09-30 | 21.70% |
| 2023-06-30 | 20.56% |
| 2023-03-31 | 18.59% |
| 2022-12-31 | 18.51% |
| 2022-09-30 | 17.80% |
| 2022-06-30 | 18.85% |
| 2022-03-31 | 20.43% |
| 2021-12-31 | 13.85% |
| 2021-09-30 | 17.05% |
| 2021-06-30 | 19.41% |
| 2021-03-31 | 19.62% |
| 2020-12-31 | 15.08% |
| 2020-09-30 | 17.31% |
| 2020-06-30 | 18.92% |
| 2020-03-31 | 23.86% |
| 2019-12-31 | 16.87% |
| 2019-09-30 | 17.45% |
| 2019-06-30 | 14.44% |
| 2019-03-31 | 18.27% |
| 2018-12-31 | 15.00% |
| 2018-09-30 | 17.80% |
| 2018-06-30 | 18.04% |
| 2018-03-31 | 17.87% |
| 2017-12-31 | 12.63% |
| 2017-09-30 | 16.60% |
| 2017-06-30 | 15.27% |
| 2017-03-31 | 13.73% |
| 2016-12-31 | 9.72% |
| 2016-09-30 | 12.06% |
| 2016-06-30 | 13.50% |
| 2016-03-31 | 14.10% |
| 2015-12-31 | 12.04% |
| 2015-09-30 | 16.65% |
| 2015-06-30 | 13.08% |
| 2015-03-31 | 17.06% |
| 2014-12-31 | 15.92% |
| 2014-09-30 | 16.97% |
| 2014-06-30 | 16.08% |
| 2014-03-31 | 14.86% |
| 2013-12-31 | 14.98% |
| 2013-09-30 | 17.58% |
| 2013-06-30 | 18.81% |
| 2013-03-31 | 17.03% |
| 2012-12-31 | 18.78% |
| 2012-09-30 | 20.49% |
| 2012-06-30 | 21.72% |
| 2012-03-31 | 16.37% |
| 2011-12-31 | 20.67% |
| 2011-09-30 | 20.20% |
| 2011-06-30 | 21.19% |
| 2011-03-31 | 19.45% |
| 2010-12-31 | 15.43% |
| 2010-09-30 | 17.05% |
| 2010-06-30 | 21.51% |
| 2010-03-31 | 18.89% |
| 2009-12-31 | 16.98% |
| 2009-09-30 | 16.91% |
| 2009-06-30 | 21.34% |
| 2009-03-31 | 16.17% |
| 2008-12-31 | 17.15% |
| 2008-09-30 | 12.92% |
| 2008-06-30 | 14.86% |
| 2008-03-31 | 11.29% |
| 2007-12-31 | 16.68% |
| 2007-09-30 | 17.33% |
| 2007-06-30 | 13.33% |
| 2007-03-31 | 9.44% |
| 2006-12-31 | 20.53% |
| 2006-09-30 | 14.09% |
| 2006-06-30 | 9.67% |
| 2006-03-31 | 15.85% |
| 2005-12-31 | 21.91% |
| 2005-09-30 | 16.61% |
| 2005-06-30 | 10.51% |
| 2005-03-31 | 11.68% |
| 2004-12-31 | 10.54% |
| 2004-09-30 | 5.86% |
| 2004-06-30 | -1.48% |
| 2004-03-31 | 0.39% |
| 2003-12-31 | 0.33% |
| 2003-09-30 | 1.81% |
| 2003-06-30 | -5.56% |
| 2003-03-31 | -13.26% |
| 2002-12-31 | -41.82% |
| 2002-09-30 | -36.25% |